e.g. mhealth
Search Results (1 to 3 of 3 Results)
Download search results: CSV END BibTex RIS
Skip search results from other journals and go to results- 1 Interactive Journal of Medical Research
- 1 JMIR mHealth and uHealth
- 1 Journal of Medical Internet Research
- 0 Medicine 2.0
- 0 iProceedings
- 0 JMIR Research Protocols
- 0 JMIR Human Factors
- 0 JMIR Medical Informatics
- 0 JMIR Public Health and Surveillance
- 0 JMIR Serious Games
- 0 JMIR Mental Health
- 0 JMIR Rehabilitation and Assistive Technologies
- 0 JMIR Preprints
- 0 JMIR Bioinformatics and Biotechnology
- 0 JMIR Medical Education
- 0 JMIR Cancer
- 0 JMIR Challenges
- 0 JMIR Diabetes
- 0 JMIR Biomedical Engineering
- 0 JMIR Data
- 0 JMIR Cardio
- 0 JMIR Formative Research
- 0 Journal of Participatory Medicine
- 0 JMIR Dermatology
- 0 JMIR Pediatrics and Parenting
- 0 JMIR Aging
- 0 JMIR Perioperative Medicine
- 0 JMIR Nursing
- 0 JMIRx Med
- 0 JMIRx Bio
- 0 JMIR Infodemiology
- 0 Transfer Hub (manuscript eXchange)
- 0 JMIR AI
- 0 JMIR Neurotechnology
- 0 Asian/Pacific Island Nursing Journal
- 0 Online Journal of Public Health Informatics
- 0 JMIR XR and Spatial Computing (JMXR)
We explain in this viewpoint why the current health care landscape, which we will call the “evidence-based health care paradigm,” does not allow for digital therapeutics to meet user needs and values and, consequently, does not reach successful implementation. Building on our experiences as researchers in digital health, we call for a paradigm shift in health care and sketch out a future paradigm that would enable more successful evaluation and, consequently, implementation of digital therapeutics.
Interact J Med Res 2022;11(2):e39323
Download Citation: END BibTex RIS
Go back to the top of the page Skip and go to footer section
To assess the efficacy and safety of a health product, there is a need to use a specific scientific paradigm, which is “a set of principles and methods shared by a scientific community” [21]. A framework is a model for planning processes or for action plans, which brings a systematic approach to developing, managing, and evaluating interventions [22]. Regulators, researchers, and manufacturers share a consensual paradigm for drugs [19,20].
J Med Internet Res 2019;21(10):e13606
Download Citation: END BibTex RIS